US health tech company Massive Bio has appointed international business development consultancy Intralink to support its expansion into South Korea and build partnerships across the country's oncology sector.
Massive Bio provides an AI-powered platform that connects cancer patients with suitable clinical trials. The company works with global pharmaceutical companies, hospitals and oncologists to identify patients who meet the often highly specific requirements of oncology studies.
To date, Massive Bio has matched 200,000 patients with 19,000 clinical trials across 17 markets.
To support Massive Bio's expansion into South Korea, Intralink's Seoul team will build relationships with leading hospitals, diagnostic laboratories and oncologists to drive interest in the company's platform and identify opportunities for collaboration.
It will also seek partnerships that will strengthen Massive Bio's ability to connect patients in South Korea with appropriate clinical trials, while helping pharmaceutical companies recruit the patients they need.
In addition, Intralink is supporting Massive Bio's engagement with the Korean oncology community through key industry events. For example, in November, Massive Bio will join Intralink at the 2026 AACR-KCA Joint Conference on Precision Medicine in Cancer, to hold discussions with potential partners and explore opportunities for collaboration.
Selin Kurnaz, CEO of Massive Bio, said: “South Korea is an important market in our broader Asian expansion plans because of its strong oncology ecosystem, advanced healthcare infrastructure and clinical research landscape."
Massive Bio is an agentic AI and real-world data (RWD) company advancing oncology drug development, commercialization, and access to precision medicine.
